Tivic Health® Systems, Inc. (NASDAQ: TIVC), a pioneering health tech company in bioelectronic medicine, recently announced significant advancements with the grant of two new patents from the United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO). These patents highlight Tivic Health’s innovative approach to medical technology and bolster its position in the competitive health tech market.
Market Reaction and Performance
While the news was announced last week, today, Tivic Health’s stock has seen a remarkable surge, closing at $0.7020, up by $0.2500, marking a 55.31% increase. In after-hours trading, the stock continued its upward trend, reaching $0.7200, an additional 2.56% gain. This performance has captured the attention of traders and investors alike, reflecting growing confidence in Tivic Health’s future prospects.
Trading Insights
- Volatility and Opportunity:
- The day’s trading range for Tivic Health’s stock was $0.5638 – $0.8083, indicating high volatility and presenting opportunities for short-term gains. The 52-week range of $0.2810 – $11.5000 showcases the stock’s significant fluctuations over the past year, highlighting potential for both risk and reward.
- Volume and Momentum:
- With a trading volume of 104,673,695 shares, compared to an average volume of 2,861,167 shares, there is clear momentum building around Tivic Health. High trading volume often signals increased interest and can lead to further price movements.
Patent Grants: Enhancing Technological Edge
Tivic Health’s newly granted patents, US Patent 12,011,592 and European Patent EP3615133, titled “Adaptive Trigger For a Microcurrent Stimulation Device,” protect innovative methods used to identify optimal treatment points and activate treatment modes. These adaptive triggers can be programmed in various ways, improving device performance and user convenience.
Additionally, European Patent EP3615134, titled “Sinus Treatment Device With Adaptive Circuit,” secures Tivic Health’s technology for dynamically adjusting stimulation voltage during treatment. This allows for personalized, comfortable, and effective treatments, enhancing user experience.
Expert Commentary
Blake Gurfein, Chief Scientific Officer at Tivic Health, stated, “The adaptive design and personalization of treatment parameters are unique features of our intellectual property that make our existing product line effective, comfortable, and easy to use. We are committed to continuing to build a robust intellectual property portfolio supporting both current and future products, including our emerging assets in non-invasive vagus nerve stimulation.”
Company Overview and Future Prospects
Tivic Health is a commercial health tech company advancing bioelectronic medicine. Its technology leverages stimulation of the trigeminal, sympathetic, and vagus nerve structures, offering drug-free therapeutic solutions for chronic inflammatory conditions. The company’s first commercial product, ClearUP, is an FDA-approved, award-winning, handheld bioelectronic sinus device. ClearUP is clinically proven and doctor-recommended, available through online retailers and commercial distributors.
Investor Takeaway
For traders and investors, Tivic Health represents a compelling opportunity, given its recent patent approvals, robust intellectual property, and promising market performance. The significant stock price increase and high trading volume suggest strong market confidence and potential for continued growth. With its innovative technology and expanding product portfolio, Tivic Health is well-positioned to capitalize on the growing demand for bioelectronic medical solutions.
As always, investors should conduct thorough due diligence, considering both the potential risks and rewards associated with this dynamic and evolving company.
